Scalable viral vector manufacturing – Future demand and promise
Date: Mon, April 29
Time: 6:00–7:30 PM
Location: Jefferson Room
Speaker: Spencer Hoover, Director Process and Analytical Development, CCRM
Moderator: Phil Vanek, GM Cell Therapy Growth Strategy, GE Healthcare
As more cell and gene therapies reach commercial scale, the demand for quality viral vectors has increased significantly, and world-wide manufacturing capacity is struggling to keep up. Many indicators suggest next-generation therapies will require further modifications, meaning the demand for viral vectors will continue to increase. Efforts have been focused on the development of viral vector manufacturing workflows that are ready for commercial production in terms of capacity, product safety, cost, and quality. Some hardware and reagents that are traditionally used for biologics have been adapted for viral vector manufacturing, but there is a need for novel tools to enable full-scale commercial production. GE Healthcare, in conjunction with Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto, has made significant advances in scaling lentiviral vector production using a model, suspension-adapted, stable producer cell line cultured in animal-derived component-free media. From this progress, a scalable platform for downstream concentration and purification of lentiviral vectors has been developed. However, across the viral vector manufacturing field, many additional obstacles must be overcome to meet growing clinical demand and ensure safe and potent products. This educational session will provide an overview of current practices in viral vector manufacturing, including key challenges and strategies for overcoming them, and highlight what future manufacturing approaches might be. There will then be a panel discussion with subject matter experts and a breakout networking session to enable conference participants to interact with panel members and discuss the future demands of viral vector manufacturing.
Phil is General Manager of GE Healthcare’s Cell Therapy Strategy, a business initiative funded in part by GE’s investment arm, GE Ventures. GE Ventures scales ideas and grows companies that advance industries and improve lives. At GE, Phil’s team built the strategy that led to investments including BridGE@CCRM and Vitruvian Networks, as well as the acquisitions of Biosafe in Switzerland and Asymptote LTD in the UK. Prior to joining GE, Phil was Head of Innovation for Lonza’s Pharma and Biotech division. While in this role, he led a group of research scientists, process development engineers, and commercial strategists to drive new technology initiatives focused on cell, protein, and viral therapeutic manufacturing. Phil’s career has included a number of senior innovation, business, and market development positions at Becton Dickinson (BD), Invitrogen, and Life Technologies, as well as two start-up biotechnology companies in the Washington, DC area. Phil received his PhD in biochemistry and molecular biology from Georgetown University Medical Center. He subsequently held an IRTA fellowship at the National Cancer Institute in the Laboratory of Molecular Oncology and the Hollings Cancer Center in Charleston, South Carolina. Phil is an active board member of the Alliance for Regenerative Medicine and the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto. Phil has published several industry position pieces and serves on the editorial board of Cell and Gene Therapy Insights.